Robust activation of MYC-associated apoptosis by combined BCL-2/BCL-XL inhibition and AMPK activation suppressed tumor growth, offered survival benefits, and increased the infiltration and activity of immune cells in the tumor tissue. Here, BCL2L1 is linked to neoplasm.